Stock listing

OTC:BBIXF Bonus Biogroup Ltd. Stock

US listing (OTC) of Bonus Biogroup Ltd. · home listing TASE:BONS

Follow Bonus Biogroup Ltd. into a list and get an email when it puts out news.

Share price · OTC:BBIXF

$0.04 USD 0.00 (0.0%)

Close on Nov 11, 2026

Past year -50.0% · daily closes, Nov 11, 2025 – Nov 11, 2026, adjusted for splits
Day range
$0.04 – $0.04 USDNov 11, 2026
Volume
3,000 sharesNov 11, 2026
52-week range
$0.03 – $0.15 USDLowest and highest trades, Nov 12, 2025 – Nov 11, 2026
Traded on an average day
$10 USDMedian day 0 shares · 58 days with no trades · last 3 months, Aug 11, 2026 – Nov 11, 2026
Bonus Biogroup Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TASE:BONS · Home15.00 ILA (agorot)-0.50 (-3.2%)1,440,57315.7015.9015.0015.50Close on Nov 19, 2026
OTC:BBIXF$0.04 USD0.00 (0.0%)3,000$0.04$0.04$0.04$0.04Close on Nov 11, 2026

Daily closes

Last 3 months, Aug 11, 2026 – Nov 11, 2026 · OTC:BBIXF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.040.000.0%$0.04$0.04$0.043,000
$0.04-0.01-20.0%$0.04$0.04$0.04500
$0.050.000.0%$0.05$0.05$0.050
$0.050.000.0%$0.05$0.05$0.050
$0.05+0.01+25.0%$0.05$0.05$0.051,000
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.04+0.01+33.3%$0.04$0.04$0.041,000
$0.030.000.0%$0.03$0.03$0.030
$0.030.000.0%$0.03$0.03$0.030
$0.030.000.0%$0.03$0.03$0.030
$0.030.000.0%$0.03$0.03$0.030
$0.03-0.01-25.0%$0.03$0.03$0.039,200
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.04+0.01+33.3%$0.04$0.04$0.041,000
$0.030.000.0%$0.03$0.03$0.030
$0.030.000.0%$0.03$0.03$0.030
$0.03-0.01-25.0%$0.03$0.03$0.03400
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.040.000.0%$0.04$0.04$0.040
$0.04-0.04-50.0%$0.04$0.04$0.042,000
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
Ticker
OTC:BBIXF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Bonus Biogroup Ltd. news

Bonus Biogroup Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
2 in all · newest Jul 14, 2025 · oldest 2025
Decks
6 decks · latest Mar 12, 2026

Where Bonus Biogroup Ltd. is listed

ListingExchangeCountryCurrency
TASE:BONS · Home listingTASEIsraelILA
NASDAQ:BONSNASDAQUnited StatesUSD
OTC:BBIXF · This pageOTCUnited StatesUSD

Valuation

Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026

Enterprise value
182.9M ILS
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Bonus Biogroup Ltd. · TASE:BONSUS$52.22MUS$54.52Mn/an/an/an/an/an/an/a
Nordicus Partners Corp · OTC:NORDUS$54.44MUS$54.44Mn/an/an/a0.9×n/a0.0×0.45
Boundless Bio, Inc. · NASDAQ:BOLDUS$53.61M−US$9.28Mn/an/an/a0.9×n/a0.0×0.65
Xilio Therapeutics, Inc. · NASDAQ:XLOUS$53.40M−US$62.82Mn/a−1.1×n/a0.8×−20.9%0.1×0.76
Impact BioMedical, Inc. · AMEX:IBOUS$53.31MUS$53.29M33.0×1,402×n/a5.3×n/a0.0×0.06
XBiotech Inc. · NASDAQ:XBITUS$52.74M−US$52.29Mn/an/an/a0.4×n/a0.0×0.52
iBio, Inc. · NASDAQ:IBIOUS$51.45M−US$23.13Mn/a−21.5×n/a0.7×n/a0.0×2.01
Cinclus Pharma Holding AB · OMXSTO:CINPHAUS$51.17MUS$13.16Mn/a3.8×n/a2.6×−765.8%0.0×n/a
Sirnaomics Ltd. · HKEX:2257US$51.13MUS$69.20Mn/an/an/an/an/an/an/a
Aldeyra Therapeutics, Inc. · NASDAQ:ALDXUS$50.70MUS$9.72Mn/an/an/a1.4×n/a0.0×0.66
Clene Inc. · NASDAQ:CLNNUS$50.69MUS$58.31Mn/a245×n/an/an/an/a1.48
Median of the othersUS$52.10MUS$11.44M33.0×3.8×0.9×−393.3%0.0×0.66

Team and board

Officers

OfficerRole
Shai MeretzkiFounder & CEO
Atara NovakVP Research & Development
Corinne ChemounyVP Quality Assurance
Meital EnbarVP of Finance
Tomer BronshteinVP of Innovation & Corporate Development
Vered KivityVP Regulatory & Clinical Affairs
Dror Ben DavidChief Operations Officer
Yossi RauchExecutive Chairman of the Board

Board

DirectorRole
Yossi RauchExecutive Chairman of the Board
Alon ArielDirector
Benjamin ShafirDirector
Gil ShapiraDirector
Margalit AssayagDirector

Decks

DeckKindSlidesDate
IPO Roadshow (March 2026)IPO roadshow43 slidesMar 12, 2026
Investor Presentation (2025)Investor deck42 slides2025
Investor Presentation (April 2022)Investor deck55 slidesApril 2022
Investor Presentation (March 2018)Investor deck35 slidesMarch 2018
Investor Presentation (August 2016)Investor deck27 slidesAugust 2016
Investor Presentation (July 2016)Investor deck19 slidesJuly 2016

Open Decks

Financials

Annual, in ILS

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue2.76M2.79M2.76M3.37M4.10M1.61M1.34M1.14M
Gross profit-2.76M-2.79M-2.76M-3.37M-4.10M-1.61M-1.34M-1.14M
Research and development11.2M17.6M18.6M21.3M19.5M10.4M11.1M10.8M10.9M8.56M
Selling, general and administrative2.49M10.2M11.2M5.46M31.3M2.80M2.39M7.63M9.24M9.06M
Operating income-22.6M-27.8M-28.3M-37.0M-64.7M-19.4M-20.9M-18.4M-20.1M-16.0M
Depreciation and amortization2.76M2.79M2.76M2.66M1.48M1.07M1.08M197.0K163.0K410.0K
EBITDA-19.9M-25.0M-25.6M-34.4M-63.3M-18.4M-19.8M-18.3M-20.0M-15.6M
Interest expense703.0K797.0K879.0K891.0K569.0K473.0K460.0K364.0K67.0K83.0K
Income before tax-24.5M-27.8M-28.5M-38.7M-90.1M-22.0M-22.2M-18.7M-20.2M-16.0M
Income tax-15.0K-195.0K79.0K0119.0K
Net income-24.5M-27.8M-28.5M-38.7M-90.1M-22.0M-22.2M-18.7M-20.2M-16.0M
Earnings per share, basic-0.04-0.02-0.02-0.06-0.16-0.02-0.03-0.02-0.02-0.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents228.0K6.86M12.9M53.6M79.5M16.1M105.0K8.64M2.73M1.40M
Receivables624.0K92.0K250.0K505.0K1.16M410.0K102.0K424.0K1.88M642.0K
Current assets1.75M7.19M26.4M54.4M81.0M16.7M308.0K9.09M4.65M2.08M
Property, plant and equipment19.8M15.0M5.73M6.58M973.0K829.0K717.0K
Goodwill39.0K
Total assets15.4M23.4M44.9M74.6M104.3M51.4M6.99M10.2M5.58M2.90M
Accounts payable1.84M1.01M1.41M1.95M3.99M1.56M1.48M1.22M1.05M1.35M
Current liabilities14.0M7.92M5.91M7.62M8.77M16.4M15.5M12.4M12.0M10.3M
Total debt8.90M10.2M11.2M12.0M12.3M5.15M5.88M
Total liabilities21.1M16.4M15.6M18.2M19.9M20.8M20.7M13.3M12.0M10.3M
Shareholders' equity-5.66M6.96M29.3M56.4M84.4M30.7M-13.7M-3.18M-6.38M-7.36M
Shares outstanding669.7M1.17B1.17B621.1M579.1M1.03B841.5M811.7M809.6M233.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-14.9M-21.4M-26.4M-28.8M-39.8M-15.7M-13.1M-13.4M-11.8M-9.63M
Capital spending-12.0K-342.0K-824.0K-6.39M-5.81M-254.0K-187.0K-341.0K-269.0K-191.0K
Free cash flow-14.9M-21.7M-27.2M-35.2M-45.6M-16.0M-13.3M-13.8M-12.1M-9.82M
Cash from investing-12.0K12.7M-14.3M-6.29M-6.18M-254.0K-187.0K-341.0K-269.0K-180.0K
Cash from financing8.41M2.55M-1.16M2.13M113.4M31.9M4.92M19.6M13.4M6.79M
Share buybacks13.4M6.79M
Change in cash-6.63M-6.08M-40.7M-25.9M63.5M16.0M-8.54M5.92M1.32M-3.01M

Open Financials

Cap table

Built by 6ix from Bonus Biogroup Ltd.’s releases

Common shares
1,167,925,311
Fully diluted
1,167,925,311

Fully diluted

LineShares
Common shares1,167,925,311

Share count over time

CountShares
Nov 22, 20261,167,925,311

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alon ArielDirector · Since at least Nov 6, 2026
Atara NovakVP Research & Development · Since at least Nov 4, 2026
Benjamin ShafirDirector · Since at least Nov 6, 2026
Corinne ChemounyVP Quality Assurance · Since at least Nov 4, 2026
Dror Ben DavidChief Operations Officer · Since at least Nov 4, 2026
Gil ShapiraDirector · Since at least Nov 4, 2026
Margalit AssayagDirector · Since at least Nov 6, 2026
Meital EnbarVP of Finance · Since at least Nov 4, 2026
Shai MeretzkiFounder & CEO · Since at least Jul 14, 2025
Tomer BronshteinVP of Innovation & Corporate Development · Since at least Nov 4, 2026
All 12 people
PersonSeat
Vered KivityVP Regulatory & Clinical Affairs · Since at least Nov 4, 2026
Yossi RauchExecutive Chairman of the Board · Since at least Nov 6, 2026

Open People

Log in to ask 6ix AI your own questions about Bonus Biogroup Ltd.